Abbott India Ltd (ABBOTINDIA)
₹25,635.00
Mkt cap
₹54,474 Cr
P/E ratio
33.70
P/B
11.41
Div yield
2.05%
ROE
34.40%
ROCE
44.80%
EPS (TTM)
₹760.68
Book value
₹2,247
52W range
24,650–30,655
Sector
Healthcare
Price history
Previous close
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. [1] It was established in 1944. [2]
NSE ABBOTINDIABSE 500488
Health check
Mixed
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−16.38% from high₹25,635
₹24,650+4.00% from low₹30,655
Current
₹25,635.00
Prev close
₹26,145.00
Day
−1.95%
Price performance
1D
−1.51%
1W
+2.88%
1M
−5.57%
3M
−6.55%
6M
+1.08%
1Y
−14.49%
YTD
−8.85%
Financials
Revenue, profit & margin
P/E ratio
33.7×
ABBOTINDIA is 2% below the sector median of 34.4×
ABBOTINDIA33.7×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 | |
| Expenses | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 | |
| Operating Profit | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 | |
| OPM % | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% | |
| Other Income | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 | |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 | |
| Depreciation | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 | |
| Profit before tax | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 | |
| Tax % | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% | |
| Net Profit | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 | |
| EPS in Rs | 136.59 | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 | 195.43 | 176.93 | 185.86 | 201.66 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share | 525.00 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Sep 202674.99%Promoter
Promoters74.99%
FIIs0.40%0.02
DIIs8.99%0.22
Public15.62%0.23
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Abbott India | ₹25,635.00 | 33.74 | 54,474 | 2.05% | 429 | +17.13% | 1,814 | +4.33% | 44.80% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts3
Announcements5
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2026 26 Oct - Board meets November 5, 2026 to approve Q2 and half-year FY2026 results; trading window closed until November 7.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Oct - Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.Closure of Trading Window 28 SepAnnouncement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 7 Sep - Company Secretary and Compliance Officer Sangeeta Shetty resigns, effective October 28, 2026.